{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:21:19Z","timestamp":1790940079827,"version":"4.1.0"},"reference-count":189,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1016\/j.intimp.2008.10.004","type":"journal-article","created":{"date-parts":[[2008,11,9]],"date-time":"2008-11-09T10:06:08Z","timestamp":1226225168000},"page":"10-25","source":"Crossref","is-referenced-by-count":268,"title":["A review of the current use of rituximab in autoimmune diseases"],"prefix":"10.1016","volume":"9","author":[{"given":"Hakan M.","family":"G\u00fcrcan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derin B.","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel N.H.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Nitzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haris","family":"Shekhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Razzaque","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib1","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"issue":"20","key":"10.1016\/j.intimp.2008.10.004_bib2","doi-asserted-by":"crossref","first-page":"15073","DOI":"10.1074\/jbc.M701654200","article-title":"Structural basis for recognition of CD20 by therapeutic antibody Rituximab","volume":"282","author":"Du","year":"2007","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib4","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncprheum0424","article-title":"Drug insight: the mechanism of action of Rituximab in autoimmune disease\u2014the immune complex decoy hypothesis","volume":"3","author":"Taylor","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"6 suppl 12","key":"10.1016\/j.intimp.2008.10.004_bib5","first-page":"9","article-title":"Rituximab: an insider's historical perspective","volume":"27","author":"Grillo-L\u00f3pez","year":"2000","journal-title":"Semin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.intimp.2008.10.004_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/ard.2005.042648","article-title":"Update on Rituximab","volume":"64","author":"Eisenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5070\/D34NS1K655","article-title":"A review of Rituximab in cutaneous medicine","volume":"12","author":"Scheinfeld","year":"2006","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.intimp.2008.10.004_bib8","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev.immunol.19.1.595","article-title":"B cell development pathways","volume":"19","author":"Hardy","year":"2001","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.intimp.2008.10.004_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0065-2776(08)60633-1","article-title":"Self-tolerance checkpoints in B lymphocyte development","volume":"59","author":"Goodnow","year":"1995","journal-title":"Adv Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib10","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.4049\/jimmunol.125.4.1678","article-title":"Characterization of a human B lymphocyte-specific antigen","volume":"125","author":"Stashenko","year":"1980","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2008.10.004_bib11","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1002\/art.20592","article-title":"Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus","volume":"50","author":"Anolik","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib12","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines","volume":"51","author":"Cardarelli","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib13","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody Rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib14","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenko","year":"2001","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib15","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.cji.0000203081.43235.d7","article-title":"Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of Rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum","volume":"29","author":"Lefebvre","year":"2006","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by Rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib17","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, and augmented binding and ADCC activity to Rituximab among individuals expressing the Fc{gamma}RIIIA-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib18","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody Rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib19","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunp\u00e4\u00e4","year":"2000","journal-title":"Scand J Immunol"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib20","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/eji.200425920","article-title":"Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59","volume":"35","author":"Ziller","year":"2005","journal-title":"Eur J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies","volume":"24","author":"Treon","year":"2001","journal-title":"J Immunother"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1586\/14737140.7.3.257","article-title":"Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma","volume":"7","author":"Collins-Burow","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.intimp.2008.10.004_bib23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJM199005033221805","article-title":"Rheumatoid arthritis. Pathophysiology and implications for therapy","volume":"322","author":"Harris","year":"1990","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib24","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V","article-title":"Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States","volume":"41","author":"Lawrence","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"10.1016\/j.intimp.2008.10.004_bib25","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"B cell therapy for rheumatoid arthritis: the Rituximab (anti-CD20) experience","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"10.1016\/j.intimp.2008.10.004_bib26","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with Rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of Rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib28","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib30","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of Rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2008.10.004_bib31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.med.52.1.63","article-title":"Advances in the treatment of lupus nephritis","volume":"52","author":"Zimmerman","year":"2001","journal-title":"Annu Rev Med"},{"issue":"7546","key":"10.1016\/j.intimp.2008.10.004_bib32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1136\/bmj.332.7546.890","article-title":"Systemic lupus erythematosus","volume":"332","author":"D'Cruz","year":"2006","journal-title":"BMJ"},{"issue":"9561","key":"10.1016\/j.intimp.2008.10.004_bib33","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(07)60279-7","article-title":"Systemic lupus erythematosus","volume":"369","author":"D'Cruz","year":"2007","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib34","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of Rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","article-title":"Tolerance and short term efficacy of Rituximab in 43 patients with systemic autoimmune diseases","volume":"64","author":"Gottenberg","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib36","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1002\/art.21351","article-title":"B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus","volume":"52","author":"Marks","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib37","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jpeds.2006.01.041","article-title":"Rituximab therapy for childhood-onset systemic lupus erythematosus","volume":"148","author":"Willems","year":"2006","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib39","doi-asserted-by":"crossref","first-page":"R83","DOI":"10.1186\/ar1954","article-title":"Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study","volume":"8","author":"Vigna-Perez","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib40","first-page":"65","article-title":"Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002\u20132004)","volume":"24","author":"Scheinberg","year":"2006","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib41","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1002\/art.22046","article-title":"Long-term comparison of Rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment","volume":"54","author":"Smith","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of Rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with Rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib44","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of Rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib45","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/art.22629","article-title":"Six refractory lupus patients treated with Rituximab: a case series","volume":"57","author":"Gillis","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib46","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/ard.2006.067124","article-title":"B cell depletion therapy in systemic lupus erythematosus: long term follow up and predictors of response","volume":"66","author":"Ng","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib47","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1093\/rheumatology\/kei080","article-title":"B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients","volume":"44","author":"Leandro","year":"2005","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib48","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib49","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/ard.2005.044487","article-title":"Repeated B cell depletion in treatment of refractory systemic lupus erythematosus","volume":"65","author":"Ng","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10165-007-0565-z","article-title":"A multicenter phase I\/II trial of Rituximab for refractory systemic lupus erythematosus","volume":"17","author":"Tanaka","year":"2007","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib51","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1136\/ard.61.9.786","article-title":"Fcgamma receptor IIa, IIIa, and IIIb polymorphisms in German patients with systemic lupus erythematosus: association with clinical symptoms","volume":"61","author":"Manger","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2174\/187153006779025757","article-title":"Targeting B cells in SLE: the experience with Rituximab treatment (anti-CD20)","volume":"6","author":"Eisenberg","year":"2006","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2008.10.004_bib53","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/00043426-200312001-00008","article-title":"Idiopathic thrombocytopenic purpura in adults","volume":"25","author":"Provan","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.2165\/00148581-200507050-00004","article-title":"Treatment of immune thrombocytopenic purpura in children: current concepts","volume":"7","author":"Shad","year":"2005","journal-title":"Paediatr Drugs"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib55","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jpeds.2005.04.032","article-title":"Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials","volume":"147","author":"Beck","year":"2005","journal-title":"J Pediatr"},{"issue":"6 Suppl 12","key":"10.1016\/j.intimp.2008.10.004_bib56","first-page":"91","article-title":"Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients","volume":"27","author":"Bussel","year":"2000","journal-title":"Semin Oncol"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00277-002-0461-8","article-title":"Splenectomy for immune thrombocytopenic purpura: long-term results and treatment of postsplenectomy relapses","volume":"81","author":"Kumar","year":"2002","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib58","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody Rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur J Haematol"},{"issue":"6 Suppl 12","key":"10.1016\/j.intimp.2008.10.004_bib59","first-page":"99","article-title":"A pilot study of the anti-CD20 monoclonal antibody Rituximab in patients with refractory immune thrombocytopenia","volume":"27","author":"Saleh","year":"2000","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib60","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib61","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","article-title":"Variable patterns of response to Rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura","volume":"99","author":"Stasi","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib62","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.10413","article-title":"Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (Rituximab)","volume":"74","author":"Narang","year":"2003","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib63","first-page":"538","article-title":"B-cell compartment as the selective target for the treatment of immune thrombocytopenias","volume":"88","author":"Zaja","year":"2003","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.intimp.2008.10.004_bib64","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4065\/78.11.1340","article-title":"Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome","volume":"78","author":"Shanafelt","year":"2003","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2004.09.004","article-title":"Chronic immune thrombocytopenic purpura in children: assessment of Rituximab treatment","volume":"146","author":"Wang","year":"2005","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib67","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/ajh.20276","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura","volume":"78","author":"Braendstrup","year":"2005","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of Rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.intimp.2008.10.004_bib69","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/archneur.61.10.1515","article-title":"Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial","volume":"61","author":"Achiron","year":"2004","journal-title":"Arch Neurol"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib70","first-page":"1935","article-title":"Diagnosis and management of multiple sclerosis","volume":"70","author":"Calabresi","year":"2004","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.intimp.2008.10.004_bib71","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1191\/1352458505ms1224oa","article-title":"Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis\u2014results of a retrospective multicenter observational study over five years","volume":"11","author":"Haas","year":"2005","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2008.10.004_bib72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jneuroim.2006.06.029","article-title":"Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients","volume":"180","author":"Cross","year":"2006","journal-title":"J Neuroimmunol"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib73","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib74","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.21363","article-title":"Rituximab in relapsing\u2013remitting multiple sclerosis: a 72-week, open-label, phase I trial","volume":"63","author":"Bar-Or","year":"2008","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib75","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib76","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib77","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib78","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2001.03078.x","article-title":"Favourable response to therapy with the anti-CD20 monoclonal antibody Rituximab in primary chronic cold agglutinin disease","volume":"115","author":"Berentsen","year":"2001","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib79","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0609.2007.00861.x","article-title":"Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients","volume":"79","author":"D'Arena","year":"2007","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib80","first-page":"1273","article-title":"Rituximab in the treatment of refractory autoimmune cytopenias in adults","volume":"90","author":"Narat","year":"2005","journal-title":"Haematologica"},{"issue":"9292","key":"10.1016\/j.intimp.2008.10.004_bib81","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with Rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib82","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib83","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D'Arena","year":"2006","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib84","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib85","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after Rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias","volume":"50","author":"Rao","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib86","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.2005.048900","article-title":"Should Rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis?","volume":"65","author":"Flossmann","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib87","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.20717","article-title":"Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment?","volume":"52","author":"Sneller","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"5091","key":"10.1016\/j.intimp.2008.10.004_bib89","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/bmj.2.5091.265","article-title":"Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis)","volume":"2","author":"Walton","year":"1958","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib90","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib91","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1 Suppl 44","key":"10.1016\/j.intimp.2008.10.004_bib92","first-page":"S23","article-title":"Adjunction of Rituximab to steroids and immunosuppressants for refractory\/relapsing Wegener's granulomatosis: a study on 8 patients","volume":"25","author":"Brihaye","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib93","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1365-2796.2005.01494.x","article-title":"Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with Rituximab","volume":"257","author":"Eriksson","year":"2005","journal-title":"J Intern Med"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib94","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/ard.2005.044420","article-title":"Lack of efficacy of Rituximab in Wegener's granulomatosis with refractory granulomatous manifestations","volume":"65","author":"Aries","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.intimp.2008.10.004_bib95","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with Rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib96","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s10067-007-0643-9","article-title":"Rituximab for treatment-resistant extensive Wegener's granulomatosis-additive effects of a maintenance treatment with leflunomide","volume":"26","author":"Henes","year":"2007","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib97","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0889-8588(05)70111-8","article-title":"Pathophysiology and treatment of graft-versus-host disease","volume":"13","author":"Flowers","year":"1999","journal-title":"Hematol Oncol Clin North Am"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib98","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1083-8791(03)00216-7","article-title":"Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody","volume":"9","author":"Ratanatharathorn","year":"2003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib99","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1182\/blood-2004-05-1855","article-title":"Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease","volume":"104","author":"Canninga-van Dijk","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib100","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2006-01-0233","article-title":"Rituximab for steroid-refractory chronic graft-versus-host disease","volume":"108","author":"Cutler","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib101","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.bmt.1705725","article-title":"Treatment of refractory chronic GVHD with Rituximab: a GITMO study","volume":"40","author":"Zaja","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.intimp.2008.10.004_bib102","first-page":"87","article-title":"Cryoimmunoglobulins","volume":"10","author":"Grey","year":"1973","journal-title":"Semin Hematol"},{"key":"10.1016\/j.intimp.2008.10.004_bib103","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0002-9343(66)90200-2","article-title":"Cryoglobulinaemia: a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity","volume":"40","author":"Meltzer","year":"1966","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib104","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3816\/CLM.2006.n.052","article-title":"Response to Rituximab in patients with type II cryoglobulinemia","volume":"7","author":"Bryce","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib105","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of Rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib106","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib107","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1093\/ndt\/gfh469","article-title":"Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis","volume":"19","author":"Roccatello","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib108","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.transproceed.2006.06.131","article-title":"Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients","volume":"38","author":"Basse","year":"2006","journal-title":"Transplant Proc"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib109","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following Rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib111","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00000441-199808000-00006","article-title":"Thrombotic thrombocytopenic purpura: understanding a disease no longer rare","volume":"316","author":"Moake","year":"1998","journal-title":"Am J Med Sci"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib112","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2004.00678.x","article-title":"Rituximab in patients with refractory thrombotic thrombocytopenic purpura","volume":"2","author":"Sallah","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","article-title":"Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura","volume":"84","author":"Reddy","year":"2005","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib114","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with Rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib115","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","article-title":"Addition of Rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia","volume":"97","author":"Heidel","year":"2007","journal-title":"Thromb Haemost"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib116","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American\u2013European Consensus Group","volume":"61","author":"Vitali","year":"2002","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib117","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/ard.56.9.521","article-title":"Prevalence of Sj\u00f6gren's syndrome in a closed rural community","volume":"56","author":"Dafni","year":"1997","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib118","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sjogren's syndrome after two infusions of Rituximab (anti-CD20)","volume":"57","author":"Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib119","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.22604","article-title":"Will targeting B cells be the answer for Sj\u00f6gren's syndrome?","volume":"56","author":"Looney","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib120","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib121","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of Rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib122","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib123","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using Rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib124","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib125","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","article-title":"High-dose Rituximab and anti-MAG-associated polyneuropathy","volume":"66","author":"Renaud","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib126","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1529-8027.2007.00129.x","article-title":"Predictors of response to Rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M","volume":"12","author":"Benedetti","year":"2007","journal-title":"J Peripher Nerv Syst"},{"issue":"17","key":"10.1016\/j.intimp.2008.10.004_bib127","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with Rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib128","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2133.2007.07800.x","article-title":"Rituximab in the adjuvant treatment of pemphigus vulgaris: a prospective open-label pilot study in five patients","volume":"156","author":"Goh","year":"2007","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib129","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib130","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"issue":"7\u20138","key":"10.1016\/j.intimp.2008.10.004_bib131","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1345\/aph.1C299","article-title":"Diagnosis and treatment of Graves disease","volume":"37","author":"Streetman","year":"2003","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib132","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1210\/er.21.2.168","article-title":"Management of Graves' ophthalmopathy: reality and perspectives","volume":"21","author":"Bartalena","year":"2000","journal-title":"Endocr Rev"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib133","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/eje.1.02325","article-title":"Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody Rituximab: an open study","volume":"156","author":"Salvi","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib134","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1210\/jc.2006-2388","article-title":"B lymphocyte depletion with the monoclonal antibody Rituximab in Graves' disease: a controlled pilot study","volume":"92","author":"El Fassi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib135","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.critrevonc.2006.11.004","article-title":"Rituximab in the treatment of adult acquired hemophilia A: a systematic review","volume":"63","author":"Franchini","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib136","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1365-2516.2005.01170.x","article-title":"Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience","volume":"12","author":"Carcao","year":"2006","journal-title":"Haemophilia"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib137","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1182\/blood-2003-11-4075","article-title":"Selective B-cell depletion with Rituximab for the treatment of patients with acquired hemophilia","volume":"103","author":"Stasi","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib138","first-page":"84","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"96","author":"Onitilo","year":"2006","journal-title":"Thromb Haemost"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib139","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/00002826-199206000-00002","article-title":"The neurobiology of the opsoclonus\u2013myoclonus syndrome","volume":"15","author":"Pranzatelli","year":"1992","journal-title":"Clin Neuropharmacol"},{"issue":"2 Suppl 1","key":"10.1016\/j.intimp.2008.10.004_bib140","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.tmrv.2007.01.002","article-title":"Guidelines on the use of intravenous immune globulin for neurologic conditions","volume":"21","author":"Feasby","year":"2007","journal-title":"Transfus Med Rev"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib141","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","article-title":"Rituximab (anti-CD20) adjunctive therapy for opsoclonus\u2013myoclonus syndrome","volume":"28","author":"Pranzatelli","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"issue":"9388","key":"10.1016\/j.intimp.2008.10.004_bib142","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","article-title":"Polymyositis and dermatomyositis","volume":"362","author":"Dalakas","year":"2003","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.intimp.2008.10.004_bib143","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib144","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib145","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1001\/archderm.143.6.763","article-title":"A pilot trial of Rituximab in the treatment of patients with dermatomyositis","volume":"143","author":"Chung","year":"2007","journal-title":"Arch Dermatol"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib146","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of Rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib147","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib148","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1345\/aph.1K037","article-title":"Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders","volume":"41","author":"G\u00fcrcan","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.intimp.2008.10.004_bib149","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/clim.2002.5278","article-title":"Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus","volume":"105","author":"Sami","year":"2002","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2008.10.004_bib150","first-page":"377","article-title":"Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris","volume":"13","author":"Sami","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.intimp.2008.10.004_bib151","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1006\/clim.2001.5061","article-title":"Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production","volume":"100","author":"Bhol","year":"2001","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2008.10.004_bib152","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/eji.1830250521","article-title":"Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin)","volume":"25","author":"Ruiz de Souza","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2008.10.004_bib153","first-page":"211","article-title":"Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG","volume":"79","author":"Andersson","year":"1993","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib154","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.4049\/jimmunol.179.8.5571","article-title":"Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function","volume":"179","author":"Kessel","year":"2007","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cyto.2007.12.007","article-title":"Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy","volume":"41","author":"Keskin","year":"2008","journal-title":"Cytokine"},{"issue":"1\u20132","key":"10.1016\/j.intimp.2008.10.004_bib156","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jneuroim.2004.03.018","article-title":"Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis","volume":"152","author":"Reinhold","year":"2004","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.intimp.2008.10.004_bib157","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2002-05-1447","article-title":"Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin","volume":"101","author":"Bayry","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib158","doi-asserted-by":"crossref","first-page":"5358","DOI":"10.4049\/jimmunol.174.9.5358","article-title":"The influence of immune complex-bearing follicular dendritic cells on the IgM response, Ig class switching, and production of high affinity IgG","volume":"174","author":"Aydar","year":"2005","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib159","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/eji.1830250836","article-title":"Follicular dendritic cells and the maintenance of IgE responses","volume":"25","author":"Helm","year":"1995","journal-title":"Eur J Immunol."},{"key":"10.1016\/j.intimp.2008.10.004_bib160","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1126\/science.291.5503.484","article-title":"Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor","volume":"291","author":"Samuelsson","year":"2001","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib161","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of Rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib162","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/rheumatology\/keh533","article-title":"Humanized anti-CD20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibodies against Rituximab","volume":"44","author":"Tahir","year":"2005","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib163","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.clim.2006.12.006","article-title":"Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis","volume":"123","author":"Sfikakis","year":"2007","journal-title":"Clin Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib164","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/intimm\/10.12.1969","article-title":"Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic\/suppressive state","volume":"10","author":"Takahashi","year":"1998","journal-title":"Int Immunol"},{"issue":"5609","key":"10.1016\/j.intimp.2008.10.004_bib165","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.intimp.2008.10.004_bib166","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"issue":"32","key":"10.1016\/j.intimp.2008.10.004_bib167","doi-asserted-by":"crossref","first-page":"11743","DOI":"10.1073\/pnas.0403832101","article-title":"Amelioration of proteolipid protein 139\u2013151-induced encephalomyelitis in SJL mice by modified amino acid copolymers and their mechanisms","volume":"101","author":"Stern","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib168","doi-asserted-by":"crossref","first-page":"743","DOI":"10.4049\/jimmunol.163.2.743","article-title":"I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice","volume":"163","author":"Noorchashm","year":"1999","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib169","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.smim.2006.01.007","article-title":"Tr1 cells: from discovery to their clinical application","volume":"18","author":"Battaglia","year":"2006","journal-title":"Semin Immunol"},{"issue":"13","key":"10.1016\/j.intimp.2008.10.004_bib170","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1073\/pnas.0712131105","article-title":"Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice","volume":"105","author":"Stern","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib171","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.4049\/jimmunol.152.8.3777","article-title":"In vivo activation of naive T cells by antigen-presenting B cells","volume":"152","author":"Morris","year":"1994","journal-title":"J Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib172","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.4049\/jimmunol.172.8.5086","article-title":"B cell selection defects underlie the development of diabetogenic APCs in nonobese diabetic mice","volume":"172","author":"Silveira","year":"2004","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib173","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/eji.200425373","article-title":"Aberrant B1 cell migration into the thymus results in activation of CD4 T cells through its potent antigen-presenting activity in the development of murine lupus","volume":"34","author":"Sato","year":"2004","journal-title":"Eur J Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2008.10.004_bib174","doi-asserted-by":"crossref","first-page":"7433","DOI":"10.4049\/jimmunol.174.11.7433","article-title":"Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4+CD25+ T cells","volume":"174","author":"Verginis","year":"2005","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2008.10.004_bib175","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.4049\/jimmunol.178.11.7018","article-title":"Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance","volume":"178","author":"Turnquist","year":"2007","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib176","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nri1256","article-title":"Dendritic cells: emerging pharmacological targets of immunosuppressive drugs","volume":"4","author":"Hackstein","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"10.1016\/j.intimp.2008.10.004_bib177","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nri2132","article-title":"Tolerogenic dendritic cells and the quest for transplant tolerance","volume":"7","author":"Morelli","year":"2007","journal-title":"Nat Rev Immunol"},{"issue":"5588","key":"10.1016\/j.intimp.2008.10.004_bib178","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1126\/science.1073514","article-title":"Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase","volume":"297","author":"Munn","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.intimp.2008.10.004_bib179","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1002\/eji.200526121","article-title":"Copolymer effects on microglia and T cells in the central nervous system of humanized mice","volume":"35","author":"Illes","year":"2005","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.intimp.2008.10.004_bib180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/intimm\/14.1.65","article-title":"Functional expression of indoleamine 2,3-dioxygenase by murine CD8 alpha(+) dendritic cells","volume":"14","author":"Fallarino","year":"2002","journal-title":"Int Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib181","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaut.2005.11.005","article-title":"The mechanism of nasal tolerance in lupus prone mice is T-cell anergy induced by immature B cells that lack B7 expression","volume":"26","author":"Wu","year":"2006","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.intimp.2008.10.004_bib182","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.4049\/jimmunol.176.7.4021","article-title":"Induction of peripheral T cell tolerance by antigen-presenting B cells. II. Chronic antigen presentation overrules antigen-presenting B cell activation","volume":"176","author":"Raimondi","year":"2006","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.intimp.2008.10.004_bib183","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1172\/JCI118643","article-title":"Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production","volume":"97","author":"Desai-Mehta","year":"1996","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.intimp.2008.10.004_bib184","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1172\/JCI118855","article-title":"Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes","volume":"98","author":"Koshy","year":"1996","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.intimp.2008.10.004_bib185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/rheumatology\/keh443","article-title":"Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab","volume":"44","author":"Tokunaga","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.intimp.2008.10.004_bib186","doi-asserted-by":"crossref","first-page":"4772","DOI":"10.4049\/jimmunol.159.10.4772","article-title":"Induction of tolerance by IL-10-treated dendritic cells","volume":"159","author":"Steinbrink","year":"1997","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.intimp.2008.10.004_bib187","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V93.5.1634","article-title":"Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells","volume":"93","author":"Steinbrink","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib188","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.4049\/jimmunol.178.6.3447","article-title":"B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis","volume":"178","author":"Mann","year":"2007","journal-title":"J Immunol"},{"issue":"6","key":"10.1016\/j.intimp.2008.10.004_bib189","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.2006.062505","article-title":"Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis","volume":"66","author":"Toubi","year":"2007","journal-title":"Ann Rheum Dis"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576908003196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576908003196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T16:04:29Z","timestamp":1738512269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576908003196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":189,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["S1567576908003196"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2008.10.004","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}